Antidepressant use in low- middle- and high-income countries: a World Mental Health Surveys report

Author:

Kazdin Alan E.ORCID,Wu Chi-Shin,Hwang Irving,Puac-Polanco Victor,Sampson Nancy A.,Al-Hamzawi Ali,Alonso Jordi,Andrade Laura Helena,Benjet Corina,Caldas-de-Almeida José-Miguel,de Girolamo Giovanni,de Jonge Peter,Florescu Silvia,Gureje Oye,Haro Josep M.,Harris Meredith G.,Karam Elie G.,Karam Georges,Kovess-Masfety Viviane,Lee Sing,McGrath John J.,Navarro-Mateu Fernando,Nishi Daisuke,Oladeji Bibilola D.,Posada-Villa José,Stein Dan J.,Üstün T. Bedirhan,Vigo Daniel V.,Zarkov Zahari,Zaslavsky Alan M.,Kessler Ronald C.ORCID,

Abstract

Abstract Background The most common treatment for major depressive disorder (MDD) is antidepressant medication (ADM). Results are reported on frequency of ADM use, reasons for use, and perceived effectiveness of use in general population surveys across 20 countries. Methods Face-to-face interviews with community samples totaling n = 49 919 respondents in the World Health Organization (WHO) World Mental Health (WMH) Surveys asked about ADM use anytime in the prior 12 months in conjunction with validated fully structured diagnostic interviews. Treatment questions were administered independently of diagnoses and asked of all respondents. Results 3.1% of respondents reported ADM use within the past 12 months. In high-income countries (HICs), depression (49.2%) and anxiety (36.4%) were the most common reasons for use. In low- and middle-income countries (LMICs), depression (38.4%) and sleep problems (31.9%) were the most common reasons for use. Prevalence of use was 2–4 times as high in HICs as LMICs across all examined diagnoses. Newer ADMs were proportionally used more often in HICs than LMICs. Across all conditions, ADMs were reported as very effective by 58.8% of users and somewhat effective by an additional 28.3% of users, with both proportions higher in LMICs than HICs. Neither ADM class nor reason for use was a significant predictor of perceived effectiveness. Conclusion ADMs are in widespread use and for a variety of conditions including but going beyond depression and anxiety. In a general population sample from multiple LMICs and HICs, ADMs were widely perceived to be either very or somewhat effective by the people who use them.

Funder

U.S. Public Health Service

John D. and Catherine T. MacArthur Foundation

Eli Lilly and Company

Fogarty International Center

GlaxoSmithKline

Pan American Health Organization

Bristol-Myers Squibb

Pfizer Foundation

Publisher

Cambridge University Press (CUP)

Subject

Psychiatry and Mental health,Applied Psychology

Reference32 articles.

1. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial

2. Brody, D. J. , & Gu, Q. (2020). Antidepressant use among adults: United States, 2015–2018. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db377.htm.

3. Call to action regarding the vascular‐bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders

4. Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials;Zhang;Neural Regeneration Research,2013

5. How Should Remission From Depression Be Defined? The Depressed Patient’s Perspective

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3